The Correlate of Risk Targeted Intervention Study

PHASE2/PHASE3UnknownINTERVENTIONAL
Enrollment

2,927

Participants

Timeline

Start Date

September 20, 2016

Primary Completion Date

December 31, 2019

Study Completion Date

December 31, 2019

Conditions
Tuberculosis
Interventions
DRUG

Isoniazid

Participants in the Treatment Arm will receive high dose Isoniazid - 15mg per kg body weight, rounded up to the nearest 100 mg; maximum dose 900 mg with Pyridoxine supplementation (25mg).

DRUG

Rifapentine

Rifapentine based on body weight (\>32kg - 50kg: 750 mg; \>50kg: 900 mg), given weekly as 12 directly observed treatment (DOT) oral doses, ideally with food, over 3 months.

Trial Locations (5)

2571

Aurum Institute, Klerksdorp

4013

Centre for the Aids Programme of Research in South Africa (CAPRISA), Durban

6850

South African Tuberculosis Vaccine Initiative (SATVI), Worcester

7505

Stellenbosch Immunology Research Group, Cape Town

0300

Aurum Institute, Rustenburg

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

South African Tuberculosis Vaccine Initiative

OTHER

collaborator

Aurum Institute

OTHER

collaborator

Centre for the AIDS Programme of Research in South Africa

NETWORK

collaborator

University of Stellenbosch

OTHER

collaborator

London School of Hygiene and Tropical Medicine

OTHER

collaborator

Fred Hutchinson Cancer Center

OTHER

lead

University of Cape Town

OTHER